Log in to search using one of your social media accounts:

 

Bellerophon brings inhaled nitric oxide into Ph2 pulmonary hypertension trial

Bellerophon Therapeutics (NSDQ:BLPH) has enrolled the first patient in a Phase IIb study assessing its INOpulse device in patients with pulmonary hypertension due to interstitial lung disease. The company’s placebo-controlled study is slated to evaluate the safety and efficacy of pulsed, inhaled nitric oxide in patients with PH-ILD, including those with idiopathic pulmonary fibrosis, Bellerophon reported. Get the full story at out sister site, Drug Delivery Business News. The post Bellerophon brings inhaled nitric oxide into Ph2 pulmonary hypertension trial appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Bellerophon Therapeutics Source Type: news

Related Links:

Publication date: Available online 29 March 2018 Source:Pulmonary Pharmacology & Therapeutics Author(s): Theodoros Karampitsakos, Argyrios Tzouvelekis, Serafeim Chrysikos, Demosthenes Bouros, Iraklis Tsangaris, Wassim H. Fares Interstitial lung diseases (ILDs) comprise a broad and heterogeneous group of more than two hundred diseases with common functional characteristics. Their diagnosis and management require a multidisciplinary approach. This multidisciplinary approach involves the assessment of comorbid conditions including pulmonary hypertension (PH) that exerts a dramatic impact on survival. The current World He...
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research
We report a case of a 68-year-old non-smoking female with NF1, pre-capillary pulmonary hypertension (PH) and an interstitial lung pattern. Initial findings included progressive dyspnea, hypoxemia and sparse centrilobular ground-glass micronodules on high-resolution computed tomography (HRCT). Further study demonstrated a severe defect in diffusing capacity for carbon monoxide (DLCO), macrophages on bronchoalveolar lavage and pre-capillary PH on right cardiac catheterization. Surgical biopsy revealed macrophage accumulation along bronchovascular bundles and alveolar spaces and type II pneumocytes hyperplasia. Given the abse...
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
Interstitial lung disease (ILD) represents a collection of lung disorders with a lethal trajectory with few therapeutic options with the exception of lung transplantation. Various extracorporeal membrane oxygenation (ECMO) configurations have been used for bridge to transplant (BTT), yet no optimal configuration has been clearly demonstrated. Using a cardiopulmonary simulation, we assessed different ECMO configurations for patients with end-stage ILD to assess the physiologic deficits and help guide the development of new long-term pulmonary support devices. A cardiopulmonary ECMO simulation was created, and changes in hem...
Source: ASAIO Journal - Category: Medical Devices Tags: Adult Circulatory Support Source Type: research
ConclusionpPTT was found to be shorter in SSc patients. pPTT might serve as a surrogate marker of pulmonary hemodynamics in patients with SSc, even prior to the development of pulmonary hypertension.
Source: Lung - Category: Respiratory Medicine Source Type: research
ConclusionsMRI represents a promising imaging modality as an initial, single-shot study, for patients with suspected PH with the advantages of being non-invasive and having no radiation exposure.
Source: Lung - Category: Respiratory Medicine Source Type: research
Abstract The Critical Care Medicine Department of the National Institutes of Health Clinical Center and the Pulmonary Hypertension Association held a joint symposium to discuss "Challenges in Pulmonary Hypertension: Beating, Breathing, and Beyond." Communities of interest including patient advocates, clinicians, and academic investigators gathered together to raise awareness and highlight the challenges in diagnosing and treating pulmonary hypertension (PH). The current symposium focused on whether or not pulmonary arterial hypertension specific treatments are warranted as therapies for PH due to heart f...
Source: American Journal of Respiratory and Critical Care Medicine - Category: Respiratory Medicine Authors: Tags: Am J Respir Crit Care Med Source Type: research
Respirology, EarlyView.
Source: Respirology - Category: Respiratory Medicine Source Type: research
Respirology, EarlyView.
Source: Respirology - Category: Respiratory Medicine Source Type: research
Conditions:   Interstitial Lung Disease;   Pulmonary Hypertension Intervention:   Diagnostic Test: Pulmonary function test Sponsor:   Assiut University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Clinical Trials | Hypertension | Interstitial Lung Disease | Pulmonary Hypertension | Respiratory Medicine | Study